Research programme: biosimilars - Momenta Pharmaceuticals

Drug Profile

Research programme: biosimilars - Momenta Pharmaceuticals

Alternative Names: M 710; M-511

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Momenta Pharmaceuticals
  • Developer Momenta Pharmaceuticals; Mylan
  • Class Biological factors; Monoclonal antibodies; Proteins
  • Mechanism of Action CD80 antigen inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation
  • Research Cancer

Most Recent Events

  • 02 May 2017 Momenta Pharmaceuticals plans a clinical trial for M 710 in late 2017 or early 2018
  • 21 Oct 2016 Five biosimilars are in Preclinical development in USA and Europe (Momenta Pharmaceuticals pipeline, October 2016)
  • 08 Jan 2016 Biosimilar candidates licensed to Mylan worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top